GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to Be Highlighted at the AASLD President's Press Conference

LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company's therapeutic vaccine candidate for hepatitis C, will be highlighted in the president's press conference at the 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in San Francisco.

At 4 p.m. PDT on Nov. 1, AASLD President Arthur J. McCullough, M.D. will highlight data for the benefit of the media from 20 abstracts, including GlobeImmune's, in advance of the actual presentations in scientific sessions. The individual studies to be highlighted were selected from the nearly 1,600 abstracts that researchers in the field of liver disease will present at the meeting.

As previously announced, the interim data from GlobeImmune's Phase 2 clinical trial will be presented by John G. McHutchison, M.D., of Duke University, lead author of the study, in a late-breaking poster session beginning at 8 a.m. PST on Nov. 3, 2008. The analysis will include rapid virologic response (RVR) rates and viral kinetic analysis for patients who have completed the first four weeks of GI-5005 in combination with standard of care (SOC) versus SOC alone.

GlobeImmune's GI-5005 is a targeted molecular immunogen (Tarmogen®) designed to elicit a HCV-specific T-cell response. Tarmogens are whole, heat-killed recombinant S. cerevisiae yeast that express antigens from one or more disease-related proteins.

About GlobeImmune

GlobeImmune Inc. is a private company developing targeted molecular immunogens, Tarmogens®, for the treatment of cancer and infectious diseases. The company's lead product candidate, GI-5005, is a Tarmogen for the treatment of chronic hepatitis C infection. GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The company's lead oncology program, GI-4000, targets mutated versions of the Ras oncoprotein for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer.

For additional information, please visit the company's Web site at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.